Articles related to Oncology, Surgical

Hijacked Cancer Trial Raises Widespread Oncology Concerns

“If the systems of the site are compromised and being held for ransom, there would be no way to continue that trial, and [it would likely be] impossible to participate in other trials.” — Jeff Patton, MD, OneOncology

Hematology/Oncology February 17th 2026

Tags: CYBERSECURITY HEALTH INFORMATICS RESEARCH & CLINICAL TRIALS

Cancer Therapy Advisor

NCCN NSCLC Guidelines Update Staging, Emphasize Molecular Testing

“Patients with stage IB-IIIA or IIB disease should be considered for neoadjuvant and/or adjuvant systemic therapy based on biomarker testing for PD-L1 status, EGFR mutations, and ALK gene fusions.” — NCCN NSCLC Guidelines, Version 3, 2026

Oncology, Medical February 17th 2026

Tags: GUIDELINES/RECOMMENDATIONS LUNG CANCER MOLECULAR DIAGNOSTICS THORACIC SURGERY

Conexiant

Scalpel, Sutures, and Separation Notices

64% of surgeons felt their demanding schedules left insufficient time for personal relationships, and one-third screen positive for depression.

Oncology, Surgical February 6th 2026

Tags: PHYSICIAN WELL-BEING WORK-LIFE BALANCE

Oncology News Central (ONC)

“I Was a Horrible Patient”: How an Oncologist’s Own Cancer Diagnosis Changed Her Practice

“As an oncologist, when patients lost their hair, my response was, ‘Don’t worry. It will grow back.’ And it will grow back. But it really sucks as you’re waiting.” – Dr. Sue Hwang

Oncology, Medical February 2nd 2026

Tags: BREAST CANCER BREAST SURGERY PALLIATIVE CARE PATIENT-CENTERED CARE PHYSICIAN WELL-BEING PHYSICIAN-PATIENT RELATIONSHIP QUALITY OF LIFE

Cancer Therapy Advisor

Brothers Face Federal Charges for Allegedly Falsifying Clinical Trial Data to Bump Up Stock Price

The brothers falsely inflated OP-1250’s overall response rate from 9% to 17% and bumped up the expected phase II response rate from 18% to 36%.

Oncology Pharmacy February 2nd 2026

Tags: CRIME/LAW ENFORCEMENT CYBERSECURITY MEDICAL ETHICS MEDICAL FRAUD PATIENT SAFETY RESEARCH & CLINICAL TRIALS

Cancer Therapy Advisor

Optimizing Neoadjuvant Strategies in HER2+ Early-Stage and Locally Advanced Breast Cancer

Dr. Rita Rao shares her expert perspective on the goals of neoadjuvant therapy, treatment selection, and the evolving landscape of HER2-targeted strategies.

Oncology, Medical January 20th 2026

Tags: BREAST CANCER BREAST SURGERY NEOADJUVANT TREATMENT TARGETED THERAPIES

1 2 … 129 130 >>

Trending Topics:

Articles related to Oncology, Surgical

View More Articles On:

Hijacked Cancer Trial Raises Widespread Oncology Concerns

NCCN NSCLC Guidelines Update Staging, Emphasize Molecular Testing

Scalpel, Sutures, and Separation Notices

“I Was a Horrible Patient”: How an Oncologist’s Own Cancer Diagnosis Changed Her Practice

Brothers Face Federal Charges for Allegedly Falsifying Clinical Trial Data to Bump Up Stock Price

Optimizing Neoadjuvant Strategies in HER2+ Early-Stage and Locally Advanced Breast Cancer

Topics

Sources

The Healthcare Communications Network is owned and operated by IQVIA Inc. Click below to leave this site and continue to IQVIA’s Privacy Choices form

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form